Shares of Silence Therapeutics plc (LON:SLN – Get Free Report) passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 535 ($6.77) and traded as low as GBX 512 ($6.48). Silence Therapeutics shares last traded at GBX 535 ($6.77), with a volume of 913,528 shares.
Silence Therapeutics Price Performance
The company has a quick ratio of 4.36, a current ratio of 4.52 and a debt-to-equity ratio of 0.80. The firm has a market cap of £480.35 million and a PE ratio of -11.01. The stock has a 50 day moving average price of GBX 535 and a two-hundred day moving average price of GBX 535.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver.
Featured Articles
- Five stocks we like better than Silence Therapeutics
- Quiet Period Expirations Explained
- Here are the Pros and Cons of Using Options Call Debit Spreads
- Trading Stocks: RSI and Why it’s Useful
- Carmax Returns to the Bargain Basement: Buy the Dip?
- Stock Average Calculator
- Dividend Aristocrat Fastenal Goes on Sale: Buy It While It’s Down
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
